IMA Clinical Research — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

IMA Clinical Research is a private, revenue-generating clinical research services company with a nationwide network of over 15 full-service sites and 150+ satellite locations. Its business model is centered on providing clinical trial execution services to pharmaceutical sponsors and CROs, leveraging a large patient database and a flexible, decentralized operational model to accelerate enrollment. The company is actively recruiting for trials in key therapeutic areas including metabolic-liver disease (MASH), neurology (memory loss), psychiatry (depression), and obesity, indicating a focus on high-prevalence chronic conditions.

Metabolic Disease (MASH)Neurology (Memory Loss)Psychiatry (Depression)Obesity

Technology Platform

Integrated network of physical clinical trial sites and satellite locations enabled by patient-centric technology to support site-based, hybrid, and fully decentralized clinical trial (DCT) models.

Opportunities

The accelerating adoption of decentralized and hybrid trial models creates a major growth opportunity for IMA's flexible network.

Increasing regulatory emphasis on enrolling diverse patient populations plays directly to the strength of its geographically dispersed community-based sites.

The burgeoning drug development pipelines in its focus areas (MASH, obesity, neurology) ensure sustained demand for its recruitment services.

Risk Factors

Business is project-based and vulnerable to downturns in pharmaceutical R&D spending.

Intense competition from large global CROs and other site networks pressures pricing and market share.

Operational risks, including failure to meet enrollment targets or maintain data quality, could severely damage reputation and future contract wins.

Competitive Landscape

IMA competes in the fragmented clinical trial site and niche CRO space. Key competitors include large global full-service CROs (e.g., IQVIA, ICON), large dedicated site networks (e.g., Premier Research, Velocity Clinical Research), and a multitude of independent local research sites. IMA's differentiation is its owned-and-operated site network combined with a flexible, decentralized trial service model.

More companies in Digital Health & Biotech SaaS →More companies in United States →